SOLICITATION NOTICE
66 -- Symbiosis Pharma instrument for development fo a totally automated solid-phase extraction (SPE) method
- Notice Date
- 4/16/2009
- Notice Type
- Justification and Approval (J&A)
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, NMLC, 693 Neiman Street, FT Detrick, Maryland, 21702-9203, United States
- ZIP Code
- 21702-9203
- Solicitation Number
- N62645-09-R-0019
- Archive Date
- 5/16/2009
- Point of Contact
- Tameka N Davis, Phone: 301-619-1677, Shannon Lertora,, Phone: (301) 619-0287
- E-Mail Address
-
tameka.davis@med.navy.mil, shannon.lertora@med.navy.mil
- Small Business Set-Aside
- N/A
- Award Number
- N62645-09-P-2114
- Award Date
- 4/16/2009
- Description
- JUSTIFICATION AND APPROVAL FOR OTHER THAN FULL AND OPEN COMPETITION 1. Identify the agency and contracting activity. This Justification and Approval (J&A) for Other Than Full and Open Competition is executed by the Naval Medical Logistics Command (NMLC), Fort Detrick, MD, on behalf of the Navy and DoD Drug Testing Program Offices. 2. Nature/description of action/contract type. This action is for the award of a firm fixed priced contract on an other than full and open competition basis to Spark Holland, for a Symbiosis Pharma instrument. 3. Description of supplies/services. The Navy and DoD Drug Testing Program Offices have a requirement for a Symbiosis Pharma instrument to be used by the military drug testing laboratory, Navy Drug Screening Lab (NDSL) San Diego, for development of a totally automated solid-phase extraction (SPE) method. 4. Identification of statutory authority. The statutory exception permitting other than full and open competition for this acquisition is 10 U.S.C. 2304(c)(1), Only One Responsible Source as implemented by paragraph 6.302-1(c) of the Federal Acquisition Regulation. 5. Demonstration of contractor's unique qualifications. Spark Holland is the only supplier of an entirely automated solid-phase extraction instrument. It is unique in nature, and automates the SPE process for the extraction of drugs of abuse prior to LC-MS-MS analysis. The automated method saves time and manpower, completely automating a manual process that requires manual label transfers and is hence vulnerable to human error. Automating processes reduces the possibility of errors and improves forensic integrity of the testing process. There is no other company in the current analytical chemistry market that supplies an online extraction device that is automated and elimiates the need for human interference. An automated system decreases errors due to manual interference and therefore is better relied upon in court cases. The Spark Holland System has been proven to work with the LC-MS-MS instrument that is already installed at NDSL. This validation is both time consuming and costly. Not only is the Spark Holland the only available automated system, but duplicating the validation testing with any other company would increase cost tremendously. The San Diego lab has dedicated significant time and resources for over two years to validate and test this equipment. 6. GPE announcement/potential sources. In accordance with Federal Acquisition Regulation (FAR) 5.201, an announcement will be posted on Fedbizopps (http://www.fbo.gov) 7. Determination of fair and reasonable cost. At the time of award, the Contracting Officer will make a determination that the award price is fair and reasonable in accordance with FAR 15. 8. Description of market survey. Representatives from the NDSL San Diego have been looking at the market for this technology since 2000. They have attended the trade show PITTCON each year and have talked to vendors. Their extensive research has found that no other vendor has a completely automated system that integrates with the LC. 9. Any other supporting facts. NDSL San Diego, in support of the DoD Drug Testing Program, has committed to this line of automation research and has already developed and validated forensic drug testing analyses on a previous version of the Symbiosis Pharma instrument. This validation is both expensive and time consuming which further increases costs. 10. Listing of interested sources. Currently no other sources will be solicited. All inquires received in response to FedBizOpps announcement will be considered. 11. Actions taken to remove barriers to competition. See numbers 6 and 10 above. 12. Statement of delivery requirements. The equipment shall be delivered by April 2009. It is estimated that one instrument at $176,000 will be required for NDSL San Diego, CA. 13. Total estimated dollar value of the acquisition covered by this J&A, with funding specified by year and appropriation. $176,000.00 from FY09 OP funds 14. Reference to the approved acquisition plan. An Acquisition Plan is not required for this procurement under the criteria and thresholds established by DFARS 207.103(B). 15. Documentation for spare/repair parts acquisitions. Not applicable.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=5b2092d2b0c4aeef1ed956e7804de778&tab=core&_cview=1)
- Place of Performance
- Address: San Diego, San Diego, California, 92134, United States
- Zip Code: 92134
- Zip Code: 92134
- Record
- SN01794707-W 20090418/090416221318-5b2092d2b0c4aeef1ed956e7804de778 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |